The University of Chicago Medicine was part of a landmark clinical trial that led to approval by the U.S. Food and Drug Administration of the first oral immunotherapy treatment for peanut allergy in children and teens.
Antibiotic resistance is a growing public health problem across the globe, with many diseases becoming harder to treat. Now, a newly discovered antibiotic group shows promise in the fight against superbugs as it has a unique way of killing bacteria.
The Medicines for All Institute has entered into a partnership with a manufacturer in South Africa to commercialize advances made by the institute to improve access to lifesaving medications for HIV/AIDS and other diseases.
How can pharma and life sciences be prepared and agile enough to respond to future challenges if it has not thought about the current trends and emerging challenges?
The Protein Data Bank archive, which contains more than 160,000 3D structures for proteins, DNA, and RNA, this month released a new Coronavirus protease structure following the recent coronavirus outbreak, an ongoing viral epidemic primarily affecting mainland China that now threatens to spread to populations in other parts of the world.
An NHS electronic system which enables pharmacies to immediately check if a patient is eligible for free prescriptions is being rolled out nationally.
Researchers from the United States have found that public may be under a mistaken belief regarding the efficacy of commercially available drugs and drug promotions and bias may be the reason behind this.
In February 2020, the U.S. Food and Drug Administration (FDA) approved Palforzia, the first peanut powder product designed to help reduce the risk of severe peanut-induced allergic reactions through desensitization over time.
The U.S. Food and Drug Administrator has issued a strict warning to Purell-maker GOJO Industries, which claims it hand sanitizers can kill pathogens that cause illness in as little as 15 seconds.
A new analysis of cancer drug development by researchers at the Institute of Cancer Research, London, shows that the more revolutionary a new cancer drug is, the longer it takes to reach patients in the UK’s National Health Service healthcare system. In other words, refinements on earlier drugs or drugs which are more conventional in their effects make it to the marketplace faster
Particularly in the case of accelerated drug approvals and drugs for rare diseases (orphan drugs), the evidence available at the time of market access is often insufficient for the early benefit assessment of drugs.
Results of a new study show that a large number of physicians in the US may have received marketing payments from pharmaceutical companies that produce stimulant medications.
It turns out that in the rush to invent new drugs to treat cancers, scientists may have overlooked some obvious possibilities of existing drugs currently being used for other diseases. A new study says that therapies for diabetes, inflammation and alcoholism, and even for dog arthritis, can also result in the successful killing of cancer cells in culture.